RCS - IXICO plc - Imeka Collaboration Agreement

IXICOAnnouncement

03/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240403:nRSC0022Ja&default-theme=true

RNS Number : 0022J  IXICO plc  03 April 2024

 

 

3 April 2024

 

IXICO plc

("IXICO" or the "Company")

 

Imeka Collaboration Agreement

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, announces a collaboration
agreement with IMEKA Solutions Inc. ("Imeka") to provide access to Imeka's
suite of services for white matter(1) imaging deployed in Alzheimer's Disease
(AD) and Multiple Sclerosis (MS) clinical trials, amongst other CNS
indications.

Imeka's diffusion MRI algorithms will be made available to IXICO's global
biopharma clients, streamlining access to these tools through a combined study
delivery.  With a single contracting line, this simplifies the procurement
process whilst improving access to a broader suite of white matter imaging AI
tools and solutions delivered by IXICO.  White matter imaging is of
increasing interest for neuroinflammation, axonal integrity and myelin
integrity, in particular in AD and MS clinical trials amongst other CNS
indications.

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

''We are pleased to be partnering with Imeka to further the understanding of
debilitating neurological diseases through the power of advanced imaging
technology, in the hope that our partnership will bring clarity and
accessibility to previously untapped possibilities of image analysis."

Jean-René Bélanger, Chief Executive Officer of Imeka, commented:

"We are delighted to contribute to IXICO's outstanding imaging CRO services.
Our collaboration reflects a shared commitment to integrating advanced imaging
technologies into treatment development. By offering Imeka's expertise into
IXICO's, we anticipate the emergence of new opportunities that will ultimately
enhance patient care and provide significant benefits to patients and their
families."

 

For further information please contact:

 

 IXICO plc
 Giulio Cerroni, Chief Executive Officer  +44 (0)20 3763 7499

 Grant Nash, Chief Financial Officer

(1) White matter are areas of the brain that primarily consists of myelinated
axons. In the brain, white matter is found closer to the centre of the brain,
whereas the outer cortex is mainly grey matter

 

This is an RNS Reach announcement and the information contained is not
considered to have a significant impact on management's expectations of the
Group's performance. RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information required to
be notified under the AIM Rules for Companies, Market Abuse Regulation or
other regulation would be disseminated as an RNS regulatory announcement and
not on RNS Reach.

 

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)

 

 

About Imeka

Imeka is the global leader in white matter microstructure imaging, combining
advanced MRI processing capabilities and artificial intelligence to bring
novel insights to the research and clinical communities. The company has been
working with all major pharmaceutical companies developing treatments for
neurodegenerative diseases and is now offering its state-of-the-art technology
to physicians to directly impact patients.

More information is available on  www.imeka.ca (http://www.imeka.ca)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUAGCUPCGWP